Repligen (NASDAQ:RGEN) Issues FY24 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.42-1.49 for the period, compared to the consensus EPS estimate of $1.45. The company issued revenue guidance of $620-635 million, compared to the consensus revenue estimate of $636.53 million. Repligen also updated its FY 2024 guidance to 1.420-1.490 EPS.

Repligen Price Performance

RGEN stock traded up $8.41 on Wednesday, hitting $169.00. 958,948 shares of the company’s stock traded hands, compared to its average volume of 631,137. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.44 billion, a price-to-earnings ratio of 673.63, a P/E/G ratio of 4.62 and a beta of 0.95. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13. The stock has a fifty day moving average of $134.67 and a 200-day moving average of $166.12.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same quarter in the prior year, the firm earned $0.53 EPS. The company’s revenue was down 3.2% compared to the same quarter last year. On average, analysts forecast that Repligen will post 1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada reissued an outperform rating and set a $190.00 price target on shares of Repligen in a research note on Wednesday. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a hold rating to a buy rating and cut their price target for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. JPMorgan Chase & Co. cut their price target on shares of Repligen from $230.00 to $200.00 and set an overweight rating for the company in a research note on Thursday, May 2nd. UBS Group dropped their price objective on shares of Repligen from $205.00 to $185.00 and set a buy rating on the stock in a research report on Wednesday. Finally, Stephens reissued an overweight rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Repligen has an average rating of Moderate Buy and an average target price of $190.88.

Insider Buying and Selling at Repligen

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Martin D. Madaus acquired 1,615 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was purchased at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the purchase, the director now owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.